Predictors of joint damage in rheumatoid arthritis

APMIS

Volumn 104, Issue 2, 1996, Pages 81-93

  Wollheim, Frank A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological markers; Bone cartilage; Joint damage; Synovium

Indexed keywords

ACUTE PHASE PROTEIN; AGGRECAN; COLLAGEN TYPE 2; COLLAGEN TYPE 3; HYALURONIC ACID; NEOPTERIN;

CARTILAGE MATRIX; DISEASE ACTIVITY; HUMAN; JOINT INJURY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0029920867     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1996.tb00691.x     Document Type: Review

References (103)

1. Arend, W. P. & Dayer, J.-M.: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis. Rheum. 33: 305-315, 1990.
2. Belardelli, F.: Role of interferons and other cytokines in the regulation of the immune response. APMIS 103: 161-179, 1995.
3. Berntzen, H. B., Munthe, E. & Fagerhol, M. K.: A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J. Rheumatol. 16: 1416-1420, 1989.
4. Berthelot, J. M., Bendagoud, B., Maugars, Y., Audrain, M., Prost, A. & Youinou, P.: Antiperinuclear factors of the IgA isotype in active rheumatoid arthritis. Clin. Exp. Rheumatol. 12: 615-619, 1994.
5. Blackburn Jr., W. D.: Validity of acute phase proteins as markers of disease activity. J. Rheumatol. 21 (Suppl. 42): 9-13, 1994.
6. Boerbooms, A.: Combination therapy in rheumatoid arthritis. J. Rheumatol. 19: 500-501, 1992.
7. Bradley, H., Gough, A., Sokhi, R. S., Hassell, A., Waring, R. & Emery, P.: Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J. Rheumatol. 21: 1192-1196, 1994.
8. Brandt, K. D.: A pessimistic view of serologic markers for diagnosis and management of osteoarthritis: biochemical, immunologic, and clinicopathologic barriers. J. Rheumatol. 16 (Suppl. 18): 39-42, 1989.
9. Brun, J., Haga, H. J., Boe, E., Kallay, I., Lekven, C., Berntzen, H. B. & Fagerhol, M. K.: Calprotectin (L1) in patients with rheumatoid arthritis and in healthy controls: relation to clinical and laboratory parameters of disease activity. J. Rheumatol. 19: 859-862, 1992.
10. Caterson, B., Christner, J. E. & Baker, J. R.: Identification of a monoclonal antibody that specifically recognized corneal and skeletal keratin sulfate. Monoclonal antibodies to cartilage proteoglycan. J. Biol. Chem. 258: 8848-8854, 1983.
11. Cush, J. J., Rothlein, R., Lindsley, H. B., Mainolfi, E. A. & Lipsky, P. E.: Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. 36: 1098-1102, 1993.
12. Dawes, P. T. & Fowler, P. D.: Treatment of early rheumatoid arthritis: a review of current and future concepts and therapy. Clin. Exp. Rheumatol. 13: 381-394, 1995.
13. Delmas, P. D., Gineyts, E., Bertholin, A., Garnero, P. & Marchard, F.: Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J. Bone Miner. Res. 8: 643-648, 1993.
14. Ebeling, P. R., Peterson, J. M. & Riggs, R. L.: Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone disease. J. Bone Miner. Res. 7: 1243-1250, 1992.
15. Eberhardt, K. B. & Fex, E.: Functional impairment and disability in early rheumatoid arthritis-development over 5 years. J. Rheumatol. 22: 1037-1042, 1995.
16. Eberhardt, K., Svensson, B. & Moritz, U.: Functional assessment of early rheumatoid arthritis. Br. J. Rheumatol. 27: 364-371, 1988.
17. Eberhardt, K. B., Rydgren, L. C., Pettersson, H. & Wollheim, F. A.: Early rheumatoid arthritis - onset, course, and outcome over 2 years. Rheumatol. Int. 10: 135-142, 1990a.
18. Eberhardt, K. B., Truedsson, L., Pettersson, H., Svensson, B., Stigsson, L., Eberhardt, J. L. & Wollheim, F. A.: Disease activity and joint damage progression in early rheumatoid arthritis - relation to IgG, IgA, and IgM rheumatoid factor. Ann. Rheum. Dis. 49: 906-909, 1990b.
19. Eberhardt, K. B., Fex, E., Johnsson, K. & Geborek, P.: Hip involvement in early rheumatoid arthritis. Ann. Rheum. Dis. 54: 45-48, 1995.
20. Eberhardt, K. B., Fex, E., Johnson U. & Wollheim, F. A.: Association of HLA DRB and DQB genes with 2 and 5 year outcome in rheumatoid arthritis. Ann. Rheum. Dis. 55: 34-39, 1996.
21. Emery, P., Bradley, H., Arthur, V., Tunn, E. & Waring, R.: Genetic factors influencing the outcome of early arthritis - the role of sulphoxidation status. Br. J. Rheumatol. 31: 449-451, 1992.
22. Engström-Laurent, A. & Hällgren, R.: Circulating hyaluronate in rheumatoid arthritis: Relationship to inflammatory activity and the effect of corticosteroid therapy. Ann. Rheum. Dis. 44: 83-88, 1985.
23. Engström-Laurent, A. & Hällgren, R.: Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness. Arthritis Rheum. 30: 1333-1338, 1987.
24. Firestein, G. S., Boyle, D. L., Yu, C., Paine, M. M., Whisenand, T. D., Zvaifler, N. J. & Arend, W. P.: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37: 644-652, 1994.
25. Forslind, K., Eberhardt, K., Jonson, A. & Saxne, T.: Increased serum concentrations of cartilage oligomeric matrix protein. Prognostic marker in early rheumatoid arthritis. Br. J. Rheumatol. 31: 593-598, 1992.
26. Gough, A., Faint, J., Salmon, M., Hassel, A., Wordsworth, P., Piling, D., Birley, A. & Emery, P.: Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum. 37: 1166-1170, 1994a.
27. Gough, A. K. S., Lilley, J., Eyre, S., Holder, R. L. & Emery, P.: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344: 23-27, 1994b.
28. Gough, A. K. S., Peel, N. F. A., Eastell, R., Holder, R. L., Lilley, J. & Emery, P.: Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann. Rheum. Dis. 53: 14-17, 1994c.
29. Gregersen, P. K., Silver, J. & Winchester, R. J.: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30: 1205-1213, 1987.
30. Gudmundsson, M. & Bjelle, A.: Viscosity of plasma and blood in rheumatoid arthritis. Br. J. Rheumatol. 32: 774-779, 1993.
31. Hakala, M., Risteli, L., Manelius, J., Nieminen, P. & Risteli, J.: Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 52: 866-869, 1993.
32. Hassell, A. B., Davis, M. J., Fowler, P. D., Clarke, S., Fisher, J., Shadforth, M. F., Jones, P. W. & Dawes, P. T.: The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. Q. J. Med. 86: 601-607, 1993.
33. Hassfeld, W., Steiner, G., Hartmuth, K., Kolarz, G., Scherak, O., Graninger, W., Thumb, N. & Smolen, J. S.: Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum. 32: 1515-1520, 1989.
34. Hassfeld, W., Steiner, G., Graninger, W., Witzmann, G., Schweitzer, H. & Smolen, J. S.: Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br. J. Rheumatol. 32: 199-203, 1993.
35. Hassfeld, W., Steiner, G., Studnicka-Benke, A., Skriner, K., Graninger, W., Fischer, I. & Smolen, J. S.: Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 38: 777-785, 1995.
36. Hauschka, P. V., Lian, J. B., Cole, D. E. C. & Gundberg, C. M.: Osteocalcin and matrix G1a protein: vitamin K-dependent proteins in bone. Physiol. Rev. 69: 990-1047, 1989.
37. Heinegård, D. & Pimentel, E. R.: Cartilage matrix proteins. In: Kuettner, K. et al. (Eds.): Articular Cartilage and Osteoarthritis. Raven Press, New York 1992, pp. 95-111.
38. Hoet, R. M. & van Venrooij, W. J.: The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen, J. S., Kalden, J. R. & Maini, R. N. (Eds.): Rheumatoid Arthritis. Recent Research Advances. Springer-Verlag, Berlin Heidelberg 1992, pp. 299-318.
39. Horslev-Petersen, K., Bendtzen, K. D., Engström-Laurent, A. et al.: Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: Relation to clinical and serological parameters of inflammation during 8 and 24 months treatment with levamisole, penicillamine or azathioprine. Ann. Rheum. Dis. 47: 116-126, 1988.
40. Isenberg, D. A., Steiner, G. & Smolen, J. S.: Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J. Rheumatol. 21: 1260-1263, 1994.
41. Kavanaugh, A. F., Davis, L. S., Nichols, L. A., Norris, S. H., Rothlein, R., Scharschmidt, L. A. & Lipsky, P. E.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37: 992-999, 1994.
42. Konttinen, Y. T., Saari, H., Honkanen, V. E. A. et al.: Serum baseline hyaluronate and disease activity in rheumatoid arthritis. Clin. Chim. Acta 193: 39-48, 1990.
43. Larsen, A.: The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand. J. Rheumatol. 17: 123-129, 1988.
44. MacGregor, A. & Silman, A.: Epidemiological approaches to the immunogenetics of autoimmune rheumatic disease. Ann. Rheum. Dis. 52: 310-313, 1993.
45. Malmquist, J., Thorell, J. I. & Wollheim, F. A.: Lactoferrin and lysozyme in arthritic exudates. Acta Med. Scand. 202: 313-318, 1977.
46. McCourt, P. A. G., Ek, B., Forsberg, N. & Gustafson, S.: Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J. Biol. Chem. 269: 30081-30084, 1994.
47. Melkko, J., Niemi, S., Risteli, L. & Risteli, J.: Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36: 1238-1332, 1990.
48. Melkko, J., Hellevik, T., Risteli, L., Risteli, J. & Smedrod, B.: Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J. Exp. Med. 179: 405-412, 1994.
49. Miller, L. C., Lynch, E. A., Isa, S., Logan, J. W., Dinarello, C. D. & Steere, A. C.: Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 341: 146-148, 1993.
50. Myers, S. L., Brandt, K. D. & Eilam, O.: Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee. Implications for measurement of synovial fluid "markers" of osteoarthritis. Arthritis Rheum. 38: 1085-1091, 1995.
51. Månsson, B., Geborek, P., Saxne, T. & Björnsson, S.: Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release. Ann. Rheum. Dis. 49: 594-597, 1990.
52. Månsson, B., Carey, D., Alini, M., Ionescu, M., Rosenberg, L. C., Poole, A. R., Heinegård, D. & Saxne, T.: Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J. Clin. Invest. 95: 1071-1077, 1995.
53. Oldberg, Å., Franzén, A. & Heinegård, D.: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl. Acad. Sci. USA 83: 8819-8823, 1986.
54. Oldberg, A., Antonsson, P., Lindblom, K. & Heinegård, D.: COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J. Biol. Chem. 207: 22346-22350, 1992.
55. Paimela, L., Heiskanen, A., Kurki, P., Helve, T. & Leirisalo-Repo, M.: Serum hyaluronate levels as predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum. 34: 815-821, 1991.
56. Paimela, L., Gripenberg, M., Kurki, P. & Leirisalo-Repo, M.: Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann. Rheum. Dis. 41: 743-746, 1992.
57. Paimela, L., Leirisalo-Repo, M., Helve, T. & Koskimies, S.: The prognostic value of HLA-DR4 and B27 in early rheumatoid arthritis. Scand. J. Rheumatol. 22: 220-224, 1993.
58. Paimela, L., Leirisalo-Repo, M., Risteli, L., Hakala, M., Helve, T. & Risteli, J.: Type I collagen degradation products in serum of patients with early rheumatoid arthritis: Relationship to disease activity and radiological progression in a 3-year follow-up. Br. J. Rheumatol. 33: 1012-1016, 1994.
59. Pepys, M. B.: Acute phase proteins, C-reactive protein and serum amyloid A protein. Rheumatology in Europe 24: 26-28, 1995.
60. Pincus, T. & Callahan, L. F.: Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J. Rheumatol. 19: 1051-1057, 1992.
61. Pitsillides, A. A., Worrall, J. G., Wilkinson, L. S., Bayliss, M. T. & Edwards, J. C. W.: Hyaluronan concentration in non-inflamed and rheumatoid synovium. Br. J. Rheumatol. 33: 5-10, 1994.
62. Poole, A. R. & Dieppe, P.: Biological markers in rheumatoid arthritis. Semin. Arthritis Rheum. 23 (Suppl. 2): 17-31, 1994.
63. Poole, A. R., Witter, J., Roberts, N., Piccolo, F., Brandt, R., Paquin, J. & Baron, M.: Inflammation and cartilage metabolism in rheumatoid arthritis: studies of the blood markers hyaluronic acid, orosomucoid and keratan sulfate. Arthritis Rheum. 33: 790-799, 1990.
64. Ratcliffe, A., Shurety, W. & Caterson, B.: The quantitation of a native chondroitin sulfate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy. Arthritis Rheum. 36: 543-551, 1993.
65. Risteli, J., Elomaa, I., Niemi, S., Novamo, A. & Risteli, L.: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin. Chem. 39: 635-640, 1993.
66. Risteli, J., Niemi, S., Kauppila, S., Melkko, J. & Risteli, L.: Collagen propeptides as indicators of collagen assembly. Acta Orthop. Scand. (Suppl. 266) 66: 1-6, 1995.
67. Rizkalla, G., Reiner, A., Bogoch, E. & Poole, A. R.: Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J. Clin. Invest. 90: 2268-2277, 1992.
68. Salmon, M., Wordsworth, P., Emery, P., Tunn, E., Bacon, P. A. & Bell, J. I.: The association of HLA DRB alleles with self- and persistent forms of early symmetrical polyarthritis. Br. J. Rheumatol. 32: 628-630, 1993.
69. Saxne, T. & Heinegård, D.: Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis. Arthritis Rheum. 32: 1080-1086, 1989.
70. Saxne, T. & Heinegård, D.: Synovial fluid analyses of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis. Rheum. 35: 385-390, 1992a.
71. Saxne, T. & Heinegård, D.: Cartilage oligomeric matrix protein. A novel marker of cartilage detectable in synovial fluid and blood. Br. J. Rheumatol. 31: 583-591, 1992b.
72. Saxne, T. & Heinegård, D.: Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. Arthritis Rheum. 38: 294-296, 1995a.
73. Saxne, T. & Heinegård, D.: Matrix proteins: Potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. J. Rheumatol. (Suppl. 43) 22: 71-74, 1995b.
74. Saxne, T., Heinegård, D., Wollheim, F. A. & Pettersson, H.: Differences in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet 8447: 127-128, 1985.
75. Saxne, T., Wollheim, F. A., Pettersson, H., Heinegård, D.: Proteoglycan concentration in synovial fluid: predictor of future cartilage destruction in rheumatoid arthritis? Brit. Med. J. 295: 1447-1448, 1987.
76. Saxne, T., Glennås, A., Kvien, T. K., Mellby, K. & Heinegård, D.: Release of cartilage macromolecules into synovial fluid in acute and prolonged stages of reactive arthritis. Arthritis Rheum. 36: 20-25, 1993.
77. Saxne, T., Månsson, B., Ionescu, M., Poole, A. R. & Heinegård, D.: Aggrecan markers in synovial fluid in rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 37: S344, 1994.
78. Saxne, T., Zunino, L. & Heinegård, D.: Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum. 38: 82-90, 1995a.
79. Saxne, T., Geborek, P., Månsson, B. & Heinegård, D.: Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis. ORS abstract, 1995b.
80. Sebbag, M., Simon, M., Vincent, C., Masson-Bessière, C., Girbal, E., Durieux, J.-J. & Serre, G.: The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95: 2672-2679, 1995.
81. Seibel, M. J., Duncan, A. & Robins, S. P.: Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J. Rheumatol. 16: 964-970, 1989.
82. Seyedin, S. M., Kung, V. T., Daniloff, Y. N., Hesley, R. P., Gomez, B., Nielsen, L. A., Rosen, H. N. & Zuk, R. F.: Immunoassay for urinary pyridinoline: The new marker of bone resorption. J. Bone Min. Res. 8: 635-641, 1993.
83. Shinmei, M., Kobayashi, T., Yoshihara, Y. & Samara, A.: Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. J. Rheumatol. 22: (Suppl. 43) 78-81, 1995.
84. Silman, A. J., Epidemiology of rheumatoid arthritis. APMIS 102: 721-728, 1994.
85. Simkin, P. A., Bassett, J. E. & Koh, E.-M.: Synovial perfusion in the human knee: A methodologic analysis. Semin. Arthritis Rheum. 25: 56-66, 1995.
86. Skriner, K., Steiner, G., Sommergruber, W. H., Sinski, A. & Smolen, J. S.: Anti-RA33 autoantibodies may recognize epitopes in the N-terminal region of hnRNP-A2 (RA33). Clin. Exp. Rheumatol. 12: S79-S82, 1994.
87. Spector, T. D., Woodward, L., Hall, G. M., Hammond, A., Williams, A., Butler, M. G., James, J. T., Hart, D. J., Thompson, P. W. & Scott, D. L.: Keratan sulphate in rheumatoid arthritis, osteoarthritis and inflammatory diseases. Ann. Rheum. Dis. 51: 1134-1137, 1992.
88. Suzuki, H., Takemura, H. & Kashiwagi, H.: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum. 38: 1055-1059, 1995.
89. Thompson, P. W., Jones, D. D. & Currey, H. L. F.: Serum cytidine deaminase as an integrated measure of acute inflammation. Br. J. Rheumatol. 25: 97-98, 1986.
90. Thonar, E. J. M., Lenz, M. E., Klintworth, G. K., Caterson, B., Pachman, L. M., Glickman, P., Katz, R., Huff, J. & Kuettner, K. E.; Quantification of keratan sulphate in blood as a marker of cartilage catabolism. Arthritis Rheum. 28: 1367-1376, 1985.
91. van der Heijde, D. M., van Riel, P. L., van Leeuwen, M. A., van't Hof, M. A., van Rijswijk, M. H. & van De Putte, L. B.: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br. J. Rheumatol. 31: 519-525, 1992.
92. van Leeuwen, M. A., van Rijswijk, M. H., van der Heijde, D. M. F. M., Te Meerman, G. J., van Riel, P. L. C. M., Houtman, P. M., van De Putte, L. B. & Limburg, P. C.: The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease. Br. J. Rheumatol. 32 (Suppl. 3): 9-13, 1993.
93. van Leeuwen, M. A., Westra, J., Limburg, P. C., van Riel, P. L. C. M. & van Rijswijk, M. H.: Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann. Rheum. Dis. 54: 33-38, 1995a.
94. van Leeuwen, M. A., Westra, J., van Riel, P. L., Limburg, P. C. & van Rijswijk, M. H.: IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand. J. Rheumatol. 24: 146-153, 1995b.
95. van Rijswijk, M.: Acute phase reactants and radiological damage in rheumatoid arthritis. Rheumatology in Europe (Suppl. 2) 24: 171-172, 1995.
96. van Zeben, D., Hazes, J., Zwinderman, A., Cats, A., Schreuder, G., D'Amaro, J. & Breedveld, F.: Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum. 34: 822-830, 1991.
97. Venn, G., Billingham, M. E. J. & Hardingham, T. E.: Increased proteoglycan synthesis in cartilage in experimental canine osteoarthritis does not reflect a permanent change in chondrocyte phenotype. Arthritis Rheum. 38: 525-532, 1995.
98. Weyand, C., Hicok, K., Conn, D. & Gronzy, J.: The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Int. Med. 117: 801-806, 1992.
99. Weyand, C. M., McCarthy, T. G. & Goronzy, J. J.: Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J. Clin. Invest. 95: 2120-2126, 1995.
100. Wollheim, F. A. & Eberhardt, K. B.: The search for laboratory measures of outcome in rheumatoid arthritis. In: Scott, D. L. (Ed.): Baillieres Clinical Rheumatology 6 No. 1, 1992, pp. 69-93.
101. Wollheim, F. A. & Saxne, T.: Markers of cartilage destruction. In: Smolen, J. S., Kalden, J. R. & Maini, R. N. (Eds): Rheumatoid Arthritis. Recent Research Advances. Springer-Verlag, Berlin Heidelberg 1992, pp. 248-262.
102. Wordsworth, B. P., Lanchbury, J. S., Sakkas, L. I., Welsh, K. I., Panayi, G. S. & Bell, J. I.: HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl. Acad. Sci. USA 86: 10049-10053, 1989.
103. Wordsworth, B. P., Stedeford, J., Rosenberg, W. M. C. & Bell, J. I.: Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and Drw10. Br. J. Rheumatol. 30: 178-180, 1991.